|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||73.69 / 89.09|
- Migraine Impact Report highlights physical, social and economic challenges of migraine -
- Reductions in the impact of genital psoriasis on sexual activity seen as early as one week -
We could be poised for even a further advance PROVIDED that we stay oversold.
- 14 abstracts include data for Taltz in genital psoriasis, baricitinib in atopic dermatitis and mirikizumab in plaque psoriasis -
Consider this LLY out of the money, bullishly biased vertical call spread expiring in April.
We are essentially buying back the shares we recently sold -- at a large discount.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Nothing has changed with fundamentals, so 'good names' have gone on sale.
'I think everybody is looking at potential combinations and consolidations,' Pfizer CEO Ian Read said on an earnings call on Tuesday, Jan. 30.
In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.
Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.
Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.
Stocks rebounded on Wednesday.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lilly (Eli) & Co , where a total of 22,032 contracts have traded so far, representing approximately 2.2 million underlying shares. That amounts to about 52.3% of LLY's average daily trading volume over the past month of 4.2 million shares.
Jim discusses the State of the Union and how it relates to defense and Nucor, the Amazon-JPMorgan-Berkshire Hathaway news, Lilly's quarter, Facebook and Microsoft.
BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'
Facebook is making itself a tough own ahead of the quarterly results.
Wall Street futures surged Wednesday following the biggest two-day decline since September 2016, powered in part by a record set of annual results for the world's biggest planemaker.
Who, out there in the health care sector, is safe?
U.S. stock futures suggest Wall Street will rebound on Wednesday, following the biggest two-day decline on Wall Street in more than two year.
Jim discusses an analyst upgrade of Allergan, the super cycle concerns of Apple and how it impacts Broadcom, defense names in the bullpen, and a busy week of earnings.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.